× خانه ژورنال ها پست ها ثبت نام ورود

نتایج جستجو برای NSCLC

تعداد نتایج: 9109  
2011
Alex Martinez-Martí, Enriqueta Felip,

The phosphatidylinositol 3-kinases (PI3Ks) are members of a family of intracellular lipid kinases that phosphorylate the 3'-hydroxyl group of phosphatidylinositol and phosphoinositides. PI3K regulate signaling pathways for neoplasia, including cell proliferation, adhesion, survival, and motility. Different classes of PI3K have distinct roles in cellular signal transduction. PI3K pathway is acti...

2006
S M Lee,

E pidermal growth factor receptor (EGFR), a receptor tyrosine kinase, is frequently overexpressed in nonsmall cell lung cancer (NSCLC). These receptors play an important role in tumour cell survival and activated phosphorylated EGFR results in the phosphorylation of downstream proteins that cause cell proliferation, invasion, metastasis, and inhibition of apoptosis. Expression appears to be dep...

2017
Anna Manzo, Agnese Montanino, Guido Carillio, Raffaele Costanzo, Claudia Sandomenico, Nicola Normanno, Maria Carmela Piccirillo, Gennaro Daniele, Francesco Perrone, Gaetano Rocco, Alessandro Morabito,

Angiogenesis is a complex biological process that plays a relevant role in sustaining the microenvironment, growth, and metastatic potential of several tumors, including non-small cell lung cancer (NSCLC). Bevacizumab was the first angiogenesis inhibitor approved for the treatment of patients with advanced NSCLC in combination with chemotherapy; however, it was limited to patients with non-squa...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2004
J P van Meerbeeck, K G Tournoy,

Lung cancer is the biggest cancer killer in Europe. Non-smallcell lung cancer (NSCLC) accounts for the vast majority of cases. The annual number of newly diagnosed patients in Europe exceeds 200 000, accounting for 20% of all cancer deaths, and on average 28% of male cancer deaths across the continent [1, 2]. In females, lung cancer accounts for 10% of deaths. Five-year survival is 9.6%, rangin...

2013
K Kovács, C Oláh, G Cserni, R Vizhányó, JP Szekeres,

Methods In a 64y o. male a squamous cell lung cancer was diagnosed in his left upper lobe by bronchoscopic brush biopsy cytology. Stage III.A cT2N2MO. He underwent the neoadjuvant treatment: received six cycles of cisplatin etoposid combination. After the restaging (Stage IBycT2NOMO) we performed a pneumonectomy and the mediastinal blockdissection, because of the involvement of the pulmonary ar...

Journal: :Thorax 2005
K Miyazaki, N Kikuchi, H Satoh, K Sekizawa, M L G Janssen-Heijnen, J W W Coebergh,

We read with interest the report by JanssenHeijnen and associates on the effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer (NSCLC). The authors concluded that the number of comorbid conditions had no significant influence on the treatment chosen for patients with non-localised disease. We share the authors’ opinion that ‘‘comorbidity had no...

2014
Marie-Anne Goyette, Jean-François Côté,

Comment on: Signe Søes, Iben Lyster Daugaard, Brita Singers Sørensen, Andreas Carus, Manuel Mattheisen, Jan Alsner, Jens Overgaard, Henrik Hager, Lise Lotte Hansen, and Lasse Sommer Kristensen. Hypomethylation and increased expression of the putative oncogene ELMO3 are associated with lung cancer development and metastases formation. Oncoscience. 2014; 1(5): 367-7.

2016
Diego L. Cortinovis, Stefania Canova, Marida Abbate, Francesca Colonese, Paolo Bidoli,

Immunotherapy is changing the treatment of non-small cell lung cancer (NSCLC). The PD-1 inhibitor nivolumab has demonstrated meaningful results in terms of efficacy with a good safety profile. The novel approach to treating NSCLC using immunotherapy still has unsolved questions and challenging issues. The main doubts regarding the optimal selection of the patient are the role of this drug in fi...

2016
Li Furong, Zheng Yuanyuan,

Lung cancer is the most common factor of cancer-related deaths and about 85% of lung cancer is non-small cell lung cancer (NSCLC). MUC1, known as the attached protein or trans-membrane protein, is a kind of protein with highly glycosylation (greater than 50%) and high molecular weight (Mr>200*103). MUC1 is overexpressed in many malignancies, and as a tumor-associated antigens (TAAs), it exposes...

2017
Ming Li, Shanhu Li, Biao Liu, Meng-Meng Gu, Shitao Zou, Bei-Bei Xiao, Lan Yu, Wei-Qun Ding, Ping-Kun Zhou, Jundong Zhou, Zeng-Fu Shang,

BACKGROUND Non-small cell lung cancer (NSCLC) is the most commonly diagnosed type of lung cancer that is associated with poor prognosis. In this study we explored the potential role of p53-induced gene 3 (PIG3) in the progression of NSCLC. METHODS Immunohistochemistry was used to determine the expression levels of PIG3 in 201 NSCLC patients. We performed in vitro studies and silenced endogeno...